Prognostic modeling in diffuse large B‐cell lymphoma in the era of immunochemotherapy: Where do we go from here?

The model and approach described by Howlader et al could form a foundation for future risk‐prediction models that incorporate data on known differences in demographic, socioeconomic, clinical, and biological factors. Data from large diffuse large B‐cell lymphoma patient cohorts that capture host and tumor genomics and known clinical prognostic factors will be necessary to provide the resources for constructing meaningful prognostic models and to establish prediction models that will allow us to limit therapy and therapy‐related toxicity for favorable subsets of patients while optimizing directed approaches for poor‐risk subsets. See also pages 3326‐34.